This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/domain/vavai/projekt/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/resource/domain/vavai/subjekt/
n16http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F11%3A10110%21RIV12-MZ0-00064165/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F11%3A10110%21RIV12-MZ0-00064165
rdf:type
skos:Concept n16:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.1586/ERA.11.38
dcterms:description
Prophylactic salpingo-oophorectomy is currently the only effective strategy available for decreasing ovarian cancer risk in BRCA1/2 mutation carriers. Significantly decreased risk of ovarian cancer associated with the use of combined oral contraceptives (COCs) was shown in the general population, which could be an alternative approach for those who do not accept risk-reducing surgery. Cohort, case control and case case studies published in English up to December 2009 reporting the association of ovarian or breast cancer risk with the use of COCs and presenting BRCA status were selected for meta-analysis. Meta-analysis of three case control studies showed a significant risk reduction of ovarian cancer in BRCA1/2 mutation carriers who were associated with any past COC use (odds ratio [OR]: 0.57; 95% Cl: 0.47-0.70; p < 0.001) and significant trend by duration of COC use (OR: 0.95; 95% Cl: 0.93-0.97; p < 0.001). No significant increase in breast cancer risk associated with COC use has been found in case control studies in BRCA1 (OR: 1.08; p = 0.250), in BRCA2 (OR: 1.03; p = 0.788) mutation carriers or in case case studies in BRCA1/2 carriers (OR: 0.80; p = 0.147). Significantly increased risk of breast cancer was only shown on a subset of cohort studies in BRCA1 mutation carriers (OR: 1.48; 95% Cl: 1.14-1.92). In conclusion, meta-analysis confirmed significantly decreased ovarian cancer risk in BRCA1/2 mutation carriers associated with the use of COCs comparable to the relative extent shown in the general population. Data on the risk of breast cancer associated with COC use in BRCA mutation carriers are heterogeneous and results are inconsistent. COCs can be considered as an alternative strategy in the chemoprevention of ovarian cancer in BRCA1 mutation carriers who do not accept prophylactic salpingo-oophorectomy above the age of 30 years. Prophylactic salpingo-oophorectomy is currently the only effective strategy available for decreasing ovarian cancer risk in BRCA1/2 mutation carriers. Significantly decreased risk of ovarian cancer associated with the use of combined oral contraceptives (COCs) was shown in the general population, which could be an alternative approach for those who do not accept risk-reducing surgery. Cohort, case control and case case studies published in English up to December 2009 reporting the association of ovarian or breast cancer risk with the use of COCs and presenting BRCA status were selected for meta-analysis. Meta-analysis of three case control studies showed a significant risk reduction of ovarian cancer in BRCA1/2 mutation carriers who were associated with any past COC use (odds ratio [OR]: 0.57; 95% Cl: 0.47-0.70; p < 0.001) and significant trend by duration of COC use (OR: 0.95; 95% Cl: 0.93-0.97; p < 0.001). No significant increase in breast cancer risk associated with COC use has been found in case control studies in BRCA1 (OR: 1.08; p = 0.250), in BRCA2 (OR: 1.03; p = 0.788) mutation carriers or in case case studies in BRCA1/2 carriers (OR: 0.80; p = 0.147). Significantly increased risk of breast cancer was only shown on a subset of cohort studies in BRCA1 mutation carriers (OR: 1.48; 95% Cl: 1.14-1.92). In conclusion, meta-analysis confirmed significantly decreased ovarian cancer risk in BRCA1/2 mutation carriers associated with the use of COCs comparable to the relative extent shown in the general population. Data on the risk of breast cancer associated with COC use in BRCA mutation carriers are heterogeneous and results are inconsistent. COCs can be considered as an alternative strategy in the chemoprevention of ovarian cancer in BRCA1 mutation carriers who do not accept prophylactic salpingo-oophorectomy above the age of 30 years.
dcterms:title
Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
skos:prefLabel
Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.
skos:notation
RIV/00064165:_____/11:10110!RIV12-MZ0-00064165
n16:predkladatel
n18:ico%3A00064165
n3:aktivita
n15:I n15:P
n3:aktivity
I, P(GP301/08/P103)
n3:cisloPeriodika
8
n3:dodaniDat
n13:2012
n3:domaciTvurceVysledku
n6:3630501 n6:3492125
n3:druhVysledku
n17:J
n3:duvernostUdaju
n19:S
n3:entitaPredkladatele
n10:predkladatel
n3:idSjednocenehoVysledku
218828
n3:idVysledku
RIV/00064165:_____/11:10110
n3:jazykVysledku
n12:eng
n3:klicovaSlova
BRCA1; BRCA2; breast cancer; combined oral contraceptives; ovarian cancer; reducing salpingo-oophorectomy; collaborative reanalysis; reproductive factors; women; noncarriers; cohort; history
n3:klicoveSlovo
n4:cohort n4:women n4:breast%20cancer n4:collaborative%20reanalysis n4:reducing%20salpingo-oophorectomy n4:noncarriers n4:ovarian%20cancer n4:reproductive%20factors n4:BRCA2 n4:history n4:BRCA1 n4:combined%20oral%20contraceptives
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[86B1480E6FD1]
n3:nazevZdroje
Expert Review of Anticancer Therapy
n3:obor
n14:FK
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
4
n3:projekt
n7:GP301%2F08%2FP103
n3:rokUplatneniVysledku
n13:2011
n3:svazekPeriodika
11
n3:tvurceVysledku
Dušek, L. Zikán, Michal Cibula, David Majek, O.
n3:wos
000294978600012
s:issn
1473-7140
s:numberOfPages
11